Verily has raised a $300 million investment round led by Series X Capital to accelerate its artificial intelligence and precision health initiatives, while formally transitioning away from Alphabet’s controlling ownership. Alphabet will remain a minority investor as Verily shifts to operate as an independent entity under the new name Verily Health, following its conversion from an LLC to a corporation.
The round also includes participation from UCHealth and the University of Colorado Anschutz, reflecting expanding partnerships across health systems and academia. Verily has collaborated with both organizations on data infrastructure and research initiatives aimed at enabling AI-ready healthcare ecosystems.
“At Alphabet, we applaud Verily’s tenacity in using technology to address longstanding challenges in the healthcare industry,” said Ruth Porat. “Bringing in new investors, alongside Alphabet’s ongoing involvement, enables Verily to further scale the business to help improve patient outcomes and lower the cost of healthcare delivery through their AI health platform.”
Verily’s core platforms include Verily Pre, which underpins its data and analytics capabilities, and Verily Me, a consumer-facing application designed to deliver personalized health insights. The company is also advancing AI agents such as Violet, alongside clinical and public health tools including Lightpath for chronic disease management and Sightline for infectious disease monitoring.
“From research to care, our customers need solutions that bring the best of clinical and scientific rigor together with AI to deliver the next generation of healthcare - one that is as precise as it is personal," said Stephen Gillett.
The company outlined several areas for investment, including expansion of its Workbench platform supporting the NIH’s All of Us Research Program, as well as scaling its real-world evidence tools and data harmonization capabilities.
“This means further investment in Pre data solutions such as Workbench, which already powers the NIH’s All of Us Research Program, supporting over 21,500 researchers worldwide,” Gillett wrote.
Verily continues to deepen commercial collaborations with companies including Samsung, Salesforce, and Nvidia to integrate sensor data, streamline clinical workflows, and accelerate AI model development. Reflecting on its evolution, Gillett noted, “Over the last few years, we’ve gone through a deliberate—and honestly, sometimes difficult—transformation.”
Click here for the original news story.